Evidence map›Paper›PMID 42045910›Full record

ArticleJournal of nanobiotechnology2026

Engineered T cell membrane coated nanoparticles reverse thermo-resistance and reprogram tumor microenvironment to synergistically potentiate bladder cancer photothermal immunotherapy.

Zichen Zhong, Jian Wu, Haojie Shang, Yonghua Tong, Yu He, Qiu Huang, Xiaozhuo Ba, Wen Deng, Yongke Bai, Zhiqiang Chen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zichen Zhong *Department of Urology, Tongji Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Jian Wu *Department of Urology, Tongji Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Haojie Shang *Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Yonghua TongDepartment of Urology, Tongji Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Yu HeDepartment of Urology, Tongji Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Qiu HuangDepartment of Urology, Tongji Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Xiaozhuo BaDepartment of Urology, Tongji Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Wen DengDepartment of Urology, Tongji Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Yongke BaiDepartment of Urology, Tongji Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Zhiqiang ChenDepartment of Urology, Tongji Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. zhqchen8366@163.com.
Kun TangDepartment of Urology, Tongji Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. tangsk1990@163.com.

Funding

National Natural Science Foundation of China No.82270804, No.82470792Natural Science Foundation of Hubei Province No.2025DJA009, No.2023AFB867Shenzhen Natural Science Foundation No. JCYJ20230807143505011, 202506043006900Young Elite Scientists Sponsorship Program by CAST No. YESS20220646
6 · The paper itself

Abstract

Immunotherapy has made a breakthrough in the treatment of advanced bladder cancer, but the immunosuppressive tumor microenvironment (TME) leads to unsatisfactory clinical outcome. Photothermal therapy (PTT) is an emerging approach to synergistically enhance tumor immunotherapy, but its therapeutic efficacy suffers from insufficient distribution of photothermal agents and tumor thermo-resistance. Here, we have developed engineered T cell membrane coated triptolide-loaded polydopamine nanoparticles (ETM@PT), which exhibited excellent biocompatibility and tumor targeting properties. ETM@PT decreased heat shock proteins expression, inhibited cancer associated fibroblasts activation and downregulated MMP9 levels, demonstrating superior tumor suppression effects in multiple mouse bladder cancer models and synergistically enhancing anti-PD1 immunotherapy effectively. RNA sequencing further revealed the molecular mechanism of ETM@PT activating immune-related pathways and amplifying antitumor immunity. This strategy effectively reversed thermo-resistance and reprogrammed the immunosuppressive TME, representing a promising approach to clinical advanced bladder cancer therapy.

Indexed as

Cell MembraneImmunotherapyNanoparticlesPhotothermal TherapyT-LymphocytesTumor MicroenvironmentUrinary Bladder NeoplasmsAnimalsCell Line, TumorDiterpenesEpoxy CompoundsFemaleHumansIndolesMicePhenanthrenesDiterpenesEpoxy CompoundsIndolesPhenanthrenespolydopaminePolymerstriptolideBladder cancer immunotherapyCancer associated fibroblastsImmunogenic cell deathPhotothermal-immunotherapyTumor microenvironment

Identifiers

PMID42045910
PMCPMC13274058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.